Date: 2012-12-21
Type of information: Collaboration agreement
Compound: Woulgan® Biogel
Company: Biotec Pharmacon (Norway) Smith & Nephew (UK)
Therapeutic area: Metabolic diseases
Type agreement: collaboration
Action mechanism: Woulgan® Biogel is a wound healing hydrogel that contains the Company’s soluble yeast beta-glucan (SBG).
Disease: treatment of chronic wounds including treatment of diabetic foot ulcer
Details: Biotec BetaGlucans AS, a wholly-owned subsidiary of Biotec Pharmacon ASA, has signed an agreement with Smith & Nephew plc to cooperate on a market evaluation of Woulgan® Biogel.Woulgan® Biogel has successfully completed phase II trials and is expected to attain CE mark in 2013. At this point Biotec BetaGlucans and Smith & Nephew will conduct a market evaluation of the product in a limited number of centres across Europe.
Financial terms:
Latest news:
